# ReadCrysta

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/readcrysta

- Industry: Pharmaceuticals
- Headquarters: Shenzhen, China
- Website: www.readcrystal.com
- Latest round: Angel (Oct 22, 2020)
- Investors on record: 1

## About

Established in 2019 and based in Shenzhen, China, ReadCrysta is a pharmaceutical company that developed the technology of Microcrystalline Electron Diffraction (MicroED) and platform of artificial intelligence drug discovery. It has more than 30 million yuan experimental equipment, including cryo-transmission electron microscopy, protein expression and purification crystallization, structural biology. The founding team is from the MicroED Technology Invention Group of Stockholm University, Sweden. This technology was selected as one of the top ten global technological breakthroughs in science magazine in 2018. It awarded the third place in Zhichuang Cup Biomedical Group in China.

It provides the technology of structural biology and pharmaceutical solid state research that used in the filed of molecule drug structure analysis, peptide structure analysis and development, new vaccine design, enzyme engineering design. Structural biology includes MicroED, cryo-electron microscopy single particle (Cryo-EM SPA), X-ray diffraction. Pharmaceutical solid state research includes single crystal cultivation, crystal type screening, raw material preparation research.

## Funding rounds

- Angel, Oct 22, 2020 — Unity Ventures

## Investors

- Unity Ventures (https://capitalatlas.ai/funds/unity-ventures) — Angel